NSD2 and cancer: This field has just begun to be addressed and, for the moment, the number and the chemical diversity of KMT inhibitors available are limited and, more important, for some KMTs, which could be important targets in cancer therapies (like WHSC1 and KMT2), there are no inhibitors reported yet.